A Study of EMB-02 in Participants With Advanced Solid Tumors

A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors

The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be assessed.

Study Overview

• Status: Terminated
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Biological: EMB-02

Detailed Description

This is a Phase I/II, multi-center, open label, multiple-dose, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dos(s)e (RP2D[s]) for EMB-02 in patients with advanced solid tumors. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Wollongong, New South Wales, Australia, 2500
      • Southern Medical Day Care Centre
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Monash Health
    • Frankston, Victoria, Australia, 3199
      • Peninsula & South Eastern Haematology & Oncology Group (PASO)
• China
  • Beijing
    • Beijing, Beijing, China, 100000
      • Beijing Cancer Hospital
  • Fujian
    • Xiamen, Fujian, China
      • The First Affiliated Hospital of Xiamen University
  • Hebei
    • Handan, Hebei, China
      • Handan Central Hospital
  • Henan
    • Zhengzhou, Henan, China
      • Henan Provincial People's Hospital
  • Sichuan
    • Suining, Sichuan, China
      • Suining Central Hospital
• United States
  • Colorado
    • Colorado Springs, Colorado, United States, 80909
      • University of Colorado Health Medical Group
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Prisma Health-Upstate

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Willing and able to provide written informed consent.
• Phase I: Patients with histologically or cytologically confirmed locally advanced/metastatic solid tumors and have failed (progressed on, or are intolerant of) standard therapies. Moreover, the disease should be measurable or evaluable per RECIST v1.1
• Phase II Cohort A: Patients with histologically or cytologically confirmed locally advanced/metastatic melanoma, excluding uveal melanoma. > 1 prior therapy, including prior treatment with PD-1/L1(mandatory) and/or CTLA-4 inhibitors(optional). And the disease is measurable or evaluable per RECIST v1.1
• Archival tumor samples available for retrospective analysis or biopsy will be taken.
• ECOG performance status 0 or 1 for phase I, and ≤2 for phase II; life expectancy > 3 Months
• Adequate organ function to participate in the trial.
• Recovery from adverse events (AEs) related to prior anticancer therapy.
• Highly effective contraception

Exclusion Criteria:

• Patients who have active autoimmune disease or history of autoimmune disease
• History of severe irAE.
• History of severe allergic reactions
• Use of systemic corticosteroids.
• Symptomatic central nervous system metastases.
• Patients with cardiac dysfunction
• Uncontrolled diabetes mellitus with hemoglobin A1c > 8% (via medical history)
• Prior treatment with a LAG-3 inhibitor
• Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment;
• Prior organ or stem cell/bone marrow transplant.
• Concurrent malignancy < 5 years prior to entry.
• Patients with active infections.
• Major surgery < 4 weeks or minor surgery < 2 weeks prior to study treatment
• Live virus vaccines < 30 days prior to screening
• Pregnant or breast-feeding females
• Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment
• Any other serious underlying medical conditions
• Abuse on alcohol, cannabis- derived products or other drugs

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EMB-02; In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels. In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D.	Biological: EMB-02; EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of adverse events as assessed by CTCAE V5.0	Incidence and severity of AE.	Screening up to follow-up (30 days after the last dose)
Incidence of serious adverse events (SAE)	Incidence of SAE.	Screening up to follow-up (30 days after the last dose)
Incidence of dose interruptions	Incidence of dose interruptions of EMB-02 during treatment as a measure of tolerability.	Screening up to follow-up (30 days after the last dose)
Dose intensity	Actual amount of drug taken by patients divided by the planned amount.	Screening up to follow-up (30 days after the last dose)
The incidence of DLTs during the first cycle of treatment.	The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol.	First infusion to the end of Cycle 1 (each cycle is 28 days)
Antitumor activity(Objective Response Rate (ORR)	Measured by RECIST 1.1, only applicable in Phase II part	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the serum concentration-time curve (AUC) of EMB-02	Blood samples for serum PK analysis will be obtained (AUC).	Through treatment until EOT visit, expected average 6 months
Maximum serum concentration (Cmax) of EMB-02	Blood samples for serum PK analysis will be obtained (Cmax)	Through treatment until EOT visit, expected average 6 months
Trough concentration (Ctrough) of EMB-02	Blood samples for serum PK analysis will be obtained (Ctrough)	Through treatment until EOT visit, expected average 6 months
Average concentration over a dosing interval (Css, avg)of EMB-02.	Blood samples for serum PK analysis will be obtained (Css, avg).	Through treatment until EOT visit, expected average 6 months
Terminal half-life (T1/2) of EMB-02	Blood samples for serum PK analysis will be obtained (T1/2)	Through treatment until EOT visit, expected average 6 months.
Systemic clearance (CL) of EMB-02	Blood samples for serum PK analysis will be obtained (CL).	Through treatment until EOT visit, expected average 6 months
Steady state volume of distribution (Vss) of EMB-02	Blood samples for serum PK analysis will be obtained (Vss).	Through treatment until EOT visit, expected average 6 months
Progression free survival (PFS) of EMB-02 as assessed by RECIST 1.1	Preliminary anti-tumor activity of EMB-02 will be obtained (PFS).	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months
Duration of response of EMB-02 as assessed by RECIST 1.1	Preliminary anti-tumor activity of EMB-02 will be obtained (DOR).	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months
Incidence and titer of anti-drug antibodies stimulated by EMB-02	Antibodies to EMB-02 will be assessed to evaluate potential immunogenicity.	Up to End of Treatment Follow Up Period (30 days after the last dose)

Collaborators and Investigators

• Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2021
• Primary Completion (Actual): July 12, 2023
• Study Completion (Actual): March 21, 2024

Study Registration Dates

• First Submitted: October 18, 2020
• First Submitted That Met QC Criteria: November 4, 2020
• First Posted (Actual): November 5, 2020

Study Record Updates

• Last Update Posted (Actual): May 21, 2024
• Last Update Submitted That Met QC Criteria: May 17, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: Neoplasms; PD-1; LAG-3; Phase I/II; advanced solid tumor; Immuno-oncology; dose escalation; Bispecific antibody; Neoplasm Metastasis; EMB-02; cohort expansion
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: EMB02X101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No